Compare PKE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | PRTA |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 538.3M |
| IPO Year | N/A | N/A |
| Metric | PKE | PRTA |
|---|---|---|
| Price | $24.36 | $8.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 346.6K | ★ 490.1K |
| Earning Date | 01-13-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 19.30 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $66,053,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.79 |
| P/E Ratio | $55.65 | ★ N/A |
| Revenue Growth | ★ 7.54 | N/A |
| 52 Week Low | $11.97 | $4.32 |
| 52 Week High | $26.12 | $16.67 |
| Indicator | PKE | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 44.64 |
| Support Level | $23.57 | $8.23 |
| Resistance Level | $25.51 | $9.05 |
| Average True Range (ATR) | 0.99 | 0.53 |
| MACD | -0.19 | -0.07 |
| Stochastic Oscillator | 39.11 | 28.26 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.